Predictive Interim analysis indicates low probability of study meeting its primary efficacy endpoint if ...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), said it will discontinue its Phase 2 TOPAS-MSA study evaluating emrusolmin (TEV-‘286) in adults with multiple system ...

Teva Pharmaceutical Industries Ltd. ( TEVA ), On Monday, announced that it will discontinue the Phase 2 TOPAS-MSA study evaluating emrusolmin (TEV-'286) in adults with multiple system atrophy (MSA).

Teva will stop its Phase 2 TOPAS-MSA trial of emrusolmin after an interim analysis found a low likelihood of meeting the primary efficacy goal; no safety concerns were identified. The company said the ...

GAAP net income fell 16%, while adjusted EPS rose 8%. MSA closed the Autronica deal and kept its full-year outlook for low-double-digit reported sales growth.

Teva Pharmaceutical Industries is discontinuing its Phase 2 TOPAS-MSA trial of emrusolmin (TEV-'286) after an independent data monitoring ...

Pharmaceuticals, a U.S. affiliate of Teva, announced that it will discontinue the Phase 2 TOPAS-MSA study evaluating ...

Teva Pharma Industries Ltd ADRs (NYSE:TEVA) declined over 3% in premarket trading Monday after the company announced it will discontinue its Phase 2 TOPAS-MSA study of emrusolmin (TEV-'286) following ...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. TEVA, will discontinue its Phase 2 TOPAS-MSA ...

Teva ends its Phase II TOPAS-MSA emrusolmin trial in multiple system atrophy after a futility analysis. Read now to see what it means for MSA patients.

Trial met its dual primary endpoints for (1) statistically significant reduction (p=0.0168) in microglial activation as measured by TSPO PET ...

Teva stock faces a pipeline setback after an interim review found a low chance of meeting the study's main goal. No safety ...